Gouty Arthritis (Chronic) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Gouty arthritis (chronic gout) is a form of inflammatory arthritis caused by persistent deposition of monosodium urate (MSU) crystals in joints and surrounding tissues. While a single acute gout attack can be dramatic, chronic gout develops when hyperuricemia (elevated serum uric acid) is left untreated, leading to repeated attacks, tophi (chalk‑like nodules of urate crystals), and joint damage.

It most commonly affects men over 40, but women after menopause are also at risk. In the United States, about 9.2 million adults (≈4 % of the adult population) have gout, and roughly 30 % of those progress to chronic disease. The prevalence rises sharply in populations with obesity, metabolic syndrome, or renal impairment.

Symptoms

Symptoms of chronic gout may be intermittent or constant, and they often differ from the classic “podagra” (big‑toe pain) of an acute attack.

• Recurrent joint pain – Typically throbbing or burning, often starting at night and lasting days to weeks.
• Joint swelling & warmth – Affected joints feel tender, swollen, and may appear reddened.
• Tophi formation – Firm, yellow‑white nodules under the skin, most often on the ears, elbows, fingers, and Achilles tendons.
• Reduced range of motion – Chronic inflammation can limit joint mobility and cause stiffness, especially in the hands and feet.
• Persistent low‑grade fever – May accompany a flare, but high fever suggests infection.
• Kidney stones – Uric acid crystals can precipitate in the urinary tract, causing flank pain and hematuria.
• Skin changes – Overlying skin may become thin, shiny, or ulcerated over large tophi.
• Generalised fatigue – Chronic inflammation can lead to tiredness and reduced exercise tolerance.

Causes and Risk Factors

Pathophysiology

Uric acid is the end product of purine metabolism. When production exceeds renal excretion, serum uric acid rises above the solubility threshold (~6.8 mg/dL). Crystals precipitate in cooler peripheral tissues, triggering an intense inflammatory response mediated by neutrophils, cytokines (IL‑1β, TNF‑α), and the NLRP3 inflammasome.

Key Risk Factors

• Sex & age – Men 40–70 y (3–4× higher risk); post‑menopausal women.
• Genetics – Variants in SLC2A9, ABCG2, and other urate transporter genes increase susceptibility.
• Dietary purines – Red meat, organ meats, seafood, and high‑fructose corn syrup raise uric acid.
• Alcohol – Beer and spirits inhibit renal urate excretion.
• Obesity & metabolic syndrome – Insulin resistance reduces uric acid clearance.
• Renal disease – Impaired glomerular filtration limits uric acid removal.
• Medications – Diuretics, low‑dose aspirin, cyclosporine, and some chemotherapy agents.
• Other medical conditions – Hypertension, hyperlipidemia, and heart failure.

Diagnosis

Clinical Evaluation

The clinician begins with a detailed history (attack pattern, diet, medications) and a focused physical exam for joint swelling, tenderness, and tophi.

Laboratory Tests

• Serum uric acid – Elevated (>7 mg/dL in men, >6 mg/dL in women) supports the diagnosis but can be normal during an acute flare.
• Synovial fluid analysis – Arthrocentesis is the gold standard; identification of negatively birefringent MSU crystals under polarized light confirms gout.
• Complete blood count & ESR/CRP – Markers of inflammation; help differentiate gout from septic arthritis.
• Renal function panel – Creatinine, eGFR to gauge urate handling and guide medication dosing.

Imaging

• Ultrasound – Shows the “double contour” sign (urate crystal deposition on cartilage) and tophus size.
• Dual‑energy CT (DECT) – Sensitive for detecting crystal deposits even before they become palpable.
• Plain radiographs – May reveal punched‑out erosions with overhanging edges typical of chronic gout.

Treatment Options

Goals of Therapy

1. Control acute inflammation.
2. Lower serum uric acid (<6 mg/dL, <5 mg/dL for tophaceous gout).
3. Prevent flares, dissolve tophi, and preserve joint function.

Medications for Acute Flares

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – Indomethacin, naproxen, or ibuprofen (if renal function allows).
• Colchicine – 1.2 mg followed by 0.6 mg 1 hour later; effective if started within 12‑24 h.
• Corticosteroids – Oral prednisone 30–40 mg daily, or intra‑articular injection for mono‑articular disease.

Urate‑Lowering Therapy (ULT)

ULT is the cornerstone of chronic gout management.

• Allopurinol – Xanthine oxidase inhibitor; start 100 mg daily, titrate to target uric acid. Screen for HLA‑B*58:01 in Asian patients (risk of severe hypersensitivity).
• Febuxostat – Similar to allopurinol but effective in patients with mild‑to‑moderate renal impairment; monitor cardiovascular risk.
• Probenecid – Urate reabsorption inhibitor; useful when kidney function is good (eGFR > 60 mL/min).
• Lesinurad – Combined with a xanthine oxidase inhibitor to increase uric acid excretion.
• Pegloticase – Intravenous recombinant uricase for refractory gout; risk of infusion reactions, used in specialist centers.

Adjunctive Measures

• Colchicine prophylaxis – Low‑dose colchicine (0.6 mg once or twice daily) for 3–6 months after starting ULT to prevent flares.
• Tophus removal – Surgical excision for painful, infected, or function‑limiting tophi.

Lifestyle Modifications

Medication works best when paired with dietary and habits changes (see the “Living with Gouty Arthritis” section).

Living with Gouty Arthritis (Chronic)

Daily Management Tips

1. Hydration – Aim for ≥2 L water daily to aid uric acid excretion.
2. Weight control – Gradual weight loss (½–1 kg per week) reduces serum urate; avoid crash diets that increase ketosis.
3. Dietary choices – Limit purine‑rich foods (red meat, organ meats, anchovies, sardines) to <4 oz per day; emphasize low‑fat dairy, cherries, and vitamin C‑rich fruits.
4. Alcohol moderation – Keep beer and spirits <1 standard drink per day for men, <½ for women; wine has a smaller effect but still limit.
5. Physical activity – Low‑impact exercise (walking, swimming, cycling) 150 minutes weekly improves insulin sensitivity and joint health.
6. Medication adherence – Take ULT daily, even when asymptomatic; set phone or app reminders.
7. Monitor uric acid – Quarterly serum uric acid checks until target reached, then twice yearly.
8. Foot care – Inspect toes for tophi or ulceration; wear comfortable, well‑fitting shoes to avoid joint stress.
9. Stress management – Chronic inflammation can worsen with stress; consider mindfulness, yoga, or counseling.

When to Contact Your Provider

• New or worsening joint pain despite medication.
• Rapid growth of a tophus, especially if painful or draining.
• Kidney stone symptoms (flank pain, blood in urine).
• Side effects from urate‑lowering drugs (rash, liver abnormalities, severe gastrointestinal upset).

Prevention

Primary prevention focuses on maintaining serum uric acid below the solubility threshold.

• Routine screening for hyperuricemia in patients with hypertension, diabetes, obesity, or chronic kidney disease.
• Dietary patterns similar to the DASH or Mediterranean diet, which are low in saturated fat and high in fruits, vegetables, whole grains, and low‑fat dairy.
• Limit fructose – Soft drinks, fruit juice concentrates, and processed snacks high in high‑fructose corn syrup.
• Maintain adequate renal function – Control blood pressure, avoid nephrotoxic drugs, and manage protein intake per nephrology guidance.
• Medication review – Discuss with your physician whether any current drugs (e.g., thiazide diuretics) could be switched to alternatives.

Complications

If gout remains uncontrolled, several serious problems may develop:

• Joint destruction – Chronic erosive changes lead to permanent disability and deformity.
• Tophi infection – Ulcerated tophi can become secondarily infected, occasionally requiring antibiotics or surgery.
• Kidney disease – Uric acid nephrolithiasis and interstitial nephropathy increase the risk of chronic kidney disease.
• Cardiovascular disease – Meta‑analyses link hyperuricemia with hypertension, coronary artery disease, and stroke (independent risk factor).
• Metabolic syndrome progression – Persistent gout often coexists with insulin resistance, worsening diabetes control.

When to Seek Emergency Care

---

References

1. Mayo Clinic. Gout. https://www.mayoclinic.org. Accessed May 2026.
2. Centers for Disease Control and Prevention. Gout Statistics. https://www.cdc.gov. 2023.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Gout. https://www.niams.nih.gov. 2022.
4. Cleveland Clinic. Chronic Gout Management. https://my.clevelandclinic.org. 2024.
5. World Health Organization. Guidelines for the Management of Gout. 2021.
6. Dalbeth N, et al. "Advances in the Management of Gout." Ann Rheum Dis. 2023;82(5):565‑573.
7. Khanna D, et al. "2020 American College of Rheumatology Guideline for Management of Gout." Arthritis Rheumatol. 2020;72(2):279‑295.

```